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Abstract
Background—Increasing access to care and treatment for HIV-infected persons is a goal in 
Kenya’s response to the HIV epidemic. Using data from the second Kenya AIDS Indicator Survey 
(KAIS 2012), we describe coverage of services received among adults and adolescents who were 
enrolled in HIV care.
Methods—KAIS 2012 was a population-based survey that collected information from persons 
aged 15–64 years that included self-reported HIV status, and for persons reporting HIV infection, 
use of HIV care and antiretroviral therapy (ART). Blood specimens were collected and tested for 
HIV. HIV-positive specimens were tested for CD4 counts and viral load.
Results—Among 363 persons who reported HIV infection, 93.4% [95% confidence interval 
(CI): 87.2 to 99.6] had ever received HIV care. Among those receiving HIV care, 96.3% (95% CI: 
94.1 to 98.4) were using cotrimoxazole prophylaxis, and 74.6% (95% CI: 69.0 to 80.2) were 
receiving ART. A lower proportion of persons in care and not on ART reported using 
cotrimoxazole (89.5%, 95% CI: 82.5 to 96.5 compared with 98.6%, 95% CI: 97.1 to 100) and had 
a CD4 count measurement done (72.9%, 95% CI: 64.0 to 81.9 compared with 90.0%, 95% CI: 
82.8 to 97.3) than persons in care and on ART, respectively. Among persons in care and not on 
ART, 23.2% (95% CI: 6.8 to 39.7) had CD4 counts ≤350 cells per microliter. Viral suppression 
was observed in 75.3% (95% CI: 68.7 to 81.9) of persons on ART.
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Conclusions—Linkage and retention in care are high among persons with known HIV infection. 
However, improvements in care for the pre-ART population are needed. Viral suppression rates 
were comparable to developed settings.
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INTRODUCTION
With an estimated 23.5 million people living with HIV in sub-Saharan Africa by year-end 
2012, HIV remains one of the most serious health problems in the region.1 Timely access to 
HIV care and treatment significantly reduces HIV-related morbidity and improves survival 
for HIV-infected persons.2,3 In June 2011, the United Nations General Assembly High 
Level Meeting on AIDS reaffirmed the urgent need for universal access to HIV treatment by 
2015.4 During the early years of treatment scale-up in sub-Saharan Africa, attention was 
focused on initiating eligible patients on antiretroviral therapy (ART). Since then, efforts to 
maintain patients on treatment and to ensure sustained viral suppression have become 
priorities.5
In 2012, an estimated 1.2 million adults and adolescents aged 15 years to 64 years were 
living with HIV in Kenya.6 In 2011, the Kenyan government estimated that over 60% of 
persons diagnosed with HIV were receiving care,7 and in 2012, they estimated that 61% of 
treatment-eligible adults were receiving ART.7,8 The Kenya National AIDS Strategic Plan 
calls for increasing and sustaining care and treatment among HIV-infected persons to reduce 
HIV-related morbidity and mortality, HIV transmission, the number of new HIV infections, 
and the socio-economic impact of HIV.9 The Government of Kenya conducted a second 
Kenya AIDS Indicator Survey (KAIS 2012) to collect nationally representative data on HIV 
indicators including use of HIV-related care and treatment services among persons who 
were aware of their infection. Here, we report HIV care and treatment coverage among HIV-
infected persons who were aware of their HIV infection in KAIS 2012.
METHODS
Study Design, Sampling, and Population
KAIS 2012 was a national, population-based, cross-sectional household survey of adults and 
children aged 18 months to 64 years conducted from October 2012 through February 2013. 
KAIS 2012 included 9 of 10 programmatic regions in Kenya; the North Eastern region was 
not sampled because of regional insecurity. The KAIS 2012 methods have been presented in 
detail elsewhere.10 Household and individual questionnaires were administered to eligible 
and consenting respondents by trained interviewers. Information obtained included 
household and demographic characteristics, HIV testing history and status, and, among 
persons who reported HIV infection, use of HIV care and treatment services. Data were 
collected onto tablet computers (Mirus Innovations, Mississauga, Ontario, Canada) and 
transmitted electronically from the field to a central database in Nairobi without personally 
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identifying information using a virtual private network. In this article, we limited our 
analysis to persons aged 15–64 years who self-reported having HIV infection.
Laboratory technicians collected whole blood samples from participants using CD4 
stabilization tubes [Becton Dickinson (BD) Vacutainer Systems, Franklin Lakes, NJ]. At the 
end of each day, whole blood was used to prepare up to 4 S&S 903 dried blood spot (DBS) 
cards per participant using 50 μL of blood per spot (Schleicher & Schuell Bioscience Inc, 
Keene, NH). DBS samples were dried overnight on a drying rack, which was maintained at 
ambient temperature. CD4 stabilization tubes and DBS were transported several times a 
week to the National HIV Reference Laboratory (NHRL). At NHRL, DBS specimens were 
tested for HIV antibodies (Vironostika HIV-1/2 UNIF II Plus O Enzyme Immunoassay; 
BioMerieux, Marcy d’Etoile, France, and Murex HIV1.2.0 HIV Enzyme Immunoassay; 
DiaSorin, SpA, Saluggia, Italy). Specimens that tested HIV-positive were tested for CD4+ 
T-cell counts using the BD FACSCalibur flow cytometer (Becton Dickinson Biosciences, 
San Jose, CA) on whole blood samples within 7 days of blood collection. HIV-positive 
specimens were also tested for HIV RNA concentration using the Abbott M2000 Real-Time 
HIV-1 Assay (Abbott Laboratories, Abbott Park, IL) on DBS specimens. Because of 
hemolysis during transport, more than half (53.8%) of the HIV-positive specimens received 
at NHRL could not be tested for CD4+ T-cell counts.10
Measures
We classified subjects as ever in care if they reported that they had ever attended a clinic to 
receive HIV care. Subjects were classified as currently receiving HIV care if they reported 
attending the clinic within the previous 6 months. Subjects who reported that they had 
attended the clinic within the previous 3 months were classified as being retained in HIV 
care. Subjects who reported that they had never received HIV care or who reported they had 
received care in the past but not in the previous 6 months were classified as not currently 
receiving HIV care. Persons who reported using ART at the time of the survey were 
classified as currently using ART, and persons who indicated that they had never received 
ART or had received ART in the past but were not currently using ART were classified as 
not using ART. Persons were considered eligible for ART if their CD4+ T-cell count was 
350 cells per microliter or less and virally suppressed if HIV RNA concentration was <1000 
copies per milliliter.11
Data Analysis
To obtain nationally representative estimates from the sample, we calculated sampling 
weights for each individual and household based on selection probability, taking into 
account cluster-level nonparticipation for both the interview and blood specimen collection. 
These weights were used to calculate weighted percentages with 95% confidence intervals 
(CI). We used the Rao–Scott χ2 test to measure associations between categorical predictor 
and outcome variables. Associations were considered significant if the P value was <0.05. 
All analyses were performed in SAS version 9.3 (SAS Institute Inc., Cary, NC) using the 
SURVEYFREQ procedure to take into account the stratified cluster design of the survey.
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This survey protocol and activities were reviewed and approved by the Kenya Medical 
Research Institute’s Ethical Review Committee, the United States Centers for Disease 
Control and Prevention’s Institutional Review Board, and the Committee on Human 
Research of the University of California, San Francisco.
RESULTS
We identified 16,383 potential participants aged 15–64 years and interviewed 13,720 
(83.7%). Three hundred sixty-three (2.7%, 95% CI: 2.2 to 3.1) reported that they were 
previously diagnosed with HIV. Of these, 68.8% (95% CI: 64.0 to 73.7) were women, 
32.7% (95% CI: 27.5 to 37.9) were aged 30–39 years, 61.1% (95% CI: 54.4 to 67.9) were 
married or cohabiting, 41.9% (95% CI: 36.1 to 47.6) reported a primary school education or 
less, and 63.0% (95% CI: 56.8 to 69.2) had been employed in the past year (Table 1). The 
majority resided in rural areas (59.4%, 95% CI: 50.8 to 67.9). Relatively equal proportions 
of HIV-infected persons fell within the second and third lowest wealth quintiles (25.8%, 
95% CI: 18.5% to 33.2% and 24.3%, 95% CI: 18.6 to 30.0, respectively). Just over one-third 
(35.3%, 95% CI: 28.7 to 41.9) had been diagnosed with HIV infection within the 24 months 
preceding the survey. Overall 89.9% (95% CI: 86.0 to 93.7) were in care at the time of the 
survey, and a small proportion (3.5%, 95% CI: 1.2 to 5.9) had received care at some point in 
the past but were no longer in care.
The demographic characteristics of persons who were currently in care were similar to 
persons not in care (data not shown). Among persons currently in care, 69.8% (95% CI: 64.6 
to 75.0) were female, 33.8% (95% CI: 28.1 to 39.4) were aged 30–39 years, 60.9% (95% CI: 
53.7 to 68.2) were married or cohabiting, and 41.3% (95% CI: 35.0 to 47.5) had received 
primary school education or less (Table 2). We found that 81.3% (95% CI: 76.2 to 86.4) of 
persons who were currently in care had accessed care within 3 months of HIV diagnosis, 
and 83.3% (95% CI: 78.9 to 87.7) had their last clinic visit within 3 months of the survey. 
Ninety-six percent (95.3%, 95% CI: 94.1 to 98.4) of persons who were currently in care 
were taking cotrimoxazole, and 29.0% (95% CI: 22.5 to 35.4) were taking daily nutritional 
supplements. Overall, 85.7% (95% CI: 79.7 to 91.7) had ever had their CD4+ T-cell counts 
measured.
Of 326 persons currently in HIV care, 74.6% (95% CI: 69.0 to 80.2) were receiving ART 
(Table 3). A lower proportion of persons receiving ART were under 30 years of age (14.3%, 
95% CI: 9.9 to 18.6) compared with those not receiving ART (30.6%, 95% CI: 20.0 to 41.2), 
and a higher proportion of persons on ART were retained in care (87.2%, 95% CI: 82.4 to 
92.1) than persons not on ART (71.9%, 95% CI: 60.9 to 82.9). Among persons currently in 
care and not on ART, 10.5% (95% CI: 3.5 to 17.5) were not receiving cotrimoxazole 
prophylaxis, 27.1% (95% CI: 18.1 to 36.0) had never had their CD4+ T-cell counts 
measured, and 23.2% (95% CI: 6.8 to 39.7) were eligible for ART treatment based on the 
immunologic criterion at the time of the survey (CD4 ≤350 cells/μL). An additional 15.7% 
(95% CI: 2.6 to 28.8) had CD4+ T-cell counts between 351 and 500 cells per microliter. 
Among persons on ART, 75.3% (95% CI: 68.7 to 81.9) had HIV RNA concentration of 
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<1000 copies per milliliter compared with 30.2% (95% CI: 20.7 to 39.6) of persons who 
were not on ART.
DISCUSSION
The findings from KAIS 2012 provide population-level data on access to and quality of HIV 
care services among HIV-infected persons. Our data show evidence of success in linking 
HIV-infected persons who were aware of their infection into HIV care, in retaining persons 
in care, in the use of the recommended components of care including cotrimoxazole and 
ART, and in achieving viral suppression among those on ART.
Importantly, we found that 96% of HIV-infected persons currently in care were taking 
cotrimoxazole, highlighting progress since KAIS 2007, when 89% of HIV-infected persons 
who were aware of their HIV infection were taking cotrimoxazole.12 Revision of policy 
guidelines for care and treatment, decentralization of care and treatment services, capacity 
building of the health workforce, and improved procurement of supplies have contributed to 
improvements in the proportion of HIV-infected persons receiving care.13 Access to 
cotrimoxazole is used routinely by the Government of Kenya as a programmatic indicator of 
engagement in care; our results support its continued utility in approximating access to HIV 
care among HIV-infected persons. Although differences in study designs limit direct 
comparisons, the proportion of HIV diagnosed persons reporting current use of care in 
Kenya is comparable to results from other studies in the United States.14,15
Despite this progress, we also identified areas where improvement is needed. In particular, 
we found that persons who were in care but had not yet initiated ART were less likely to 
have a recent clinic visit, less likely to be receiving cotrimoxazole, and less likely to have a 
CD4+ T-cell count measurement than persons who were on ART. Moreover, nearly one-
quarter of these individuals were eligible for ART based on the current immunologic 
criterion for ART initiation in Kenya. Studies from other resource-constrained settings have 
also found suboptimal care outcomes in the pre-ART population, including high rates of loss 
to follow-up, death, and failure to return to the clinic for CD4+ T-cell count testing.16–18 To 
a large extent, a patient’s CD4+ T-cell count determines eligibility for ART initiation. 
Therefore, failure to meet timely initiation of ART based on immunologic criterion can 
result in increased morbidity and mortality. Although the reasons for these findings have not 
been fully investigated, it is possible that shortages in reagents for CD4+ T-cell count testing 
and cotrimoxazole supplies could have impacted access to these services for pre-ART 
populations. Under such circumstances, health care workers prioritize care for those in 
greatest need, such as persons receiving ART. Such differences among persons in care must 
be explored further, and if adherence to clinical care guidelines is found to be suboptimal, 
retraining of health care staff should be prioritized. Given our findings of differential care 
among persons based on receipt of ART, raising the immunologic threshold for ART 
initiation, as recommended by the World Health Organization,19 to CD4 ≤500 cells per 
microliter could potentially improve retention in care and access to recommended services, 
resulting in better clinical outcomes.
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Three-quarters of HIV-infected persons who were currently in care and on ART had 
achieved viral suppression. These findings are consistent with other studies that have 
reported that 78%–93% of persons on ART were virologically suppressed.14,15 It is possible 
that this is an underestimate of true population levels of viral suppression on ART. Because 
we did not determine the duration of ART use, some subjects may have recently started 
therapy and not yet reached viral suppression. Alternatively, because viral load monitoring 
is not currently a routine part of care, unsuppressed persons may reflect true treatment 
failures or poor adherence to ART.20,21 Our finding of viral suppression in 30% of persons 
who were not currently using ART is surprising because elite controllers of HIV infection 
are considered to be rare.22–24 Although a study of undiagnosed men in San Francisco had a 
similar finding, other factors must be considered.25 Persons receiving ART may have been 
misclassified, or laboratory error in the viral load results may have contributed to this 
finding. Furthermore, persons who reported that they were not currently receiving ART may 
have recently or temporarily discontinued treatment because of difficulty returning to the 
pharmacy for refills or insufficient drug supplies. Continued exploration of this finding is 
warranted, including a detailed assessment of respondents’ understanding of the question 
and laboratory analysis of blood samples for the presence of anti-retroviral drugs in 
untreated and suppressed persons.
There are limitations to consider when interpreting the findings from our study. First, we 
relied on self-reported data that may have underestimated the proportion of persons who 
were aware of their HIV infection and may have overestimated the use of care. Recall of 
events in the distant past may have resulted in inaccurate responses. Potential bias could 
have resulted from the substantial number of blood specimens that were hemolyzed and 
unable to be used for CD4+ T-cell measurements. However, no significant differences in 
demographic characteristics were observed between HIV-infected persons with and without 
CD4+ T-cell count data, leading us to believe that this limitation did not bias our findings. 
Finally, although the survey excluded the North Eastern region, this region has a HIV 
prevalence of <1%, and its exclusion is not likely to have impacted our findings.12
We believe that these limitations are offset by the strength of the nationally representative 
sample and that our estimates provide essential information on use of HIV-related care 
services among persons with known HIV infection. Although progress has been made in 
diagnosing and treating HIV-infected persons in Kenya, our study identified important 
priorities for the future including provision of essential medical services to persons before 
initiating ART. Our study also confirms that there is a loss of persons along the path from 
diagnosis to viral suppression, resulting in a sizable proportion of diagnosed persons in need 
of ART who are not receiving it and capable of transmitting infection. Continued 
exploration of factors that undermine providing care to all persons diagnosed with HIV 
infection and corrective interventions are needed.
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TABLE 1
Characteristics of Adults and Adolescents Who Self-Reported Being HIV Infected, Kenya AIDS Indicator 
Survey 2012
Total Unweighted, N = 363
Variable Unweighted, n* Unweighted, % Weighted % 95% CI
Sex
 Men 91 25.1 31.2 26.3 to 36.0
 Women 272 74.9 68.8 64.0 to 73.7
Age group, yrs
 15–29 77 21.2 20.5 15.9 to 25.2
 30–39 124 34.2 32.7 27.5 to 37.9
 40–49 98 27.0 29.0 23.3 to 34.7
 >50 64 17.6 17.7 13.4 to 22.1
Marital status
 Ever widowed 83 22.9 21.6 16.3 to 26.8
 Married/cohabiting 212 58.4 61.1 54.4 to 67.9
 Others 68 18.7 17.3 12.9 to 21.7
Highest educational attainment
 Primary or less 162 44.6 41.9 36.1 to 47.6
 Secondary/vocational 82 22.6 23.8 18.2 to 29.5
 College 119 32.8 34.3 27.8 to 40.8
Employed
 Yes 226 62.2 63.0 56.8 to 69.2
 No 137 37.7 37.0 30.8 to 43.2
Region
 Nairobi 37 10.2 8.4 5.6 to 11.2
 Central 34 9.4 8.7 5.1 to 12.4
 Coast 33 9.1 6.5 3.2 to 9.8
 Eastern 38 10.5 9.6 5.3 to 14.0
 Nyanza 145 39.9 40.0 31.3 to 48.8
 Rift Valley 36 9.9 15.4 8.4 to 22.4
 Western 40 11.0 11.3 5.6 to 17.0
Residence
 Rural 211 58.1 59.4 50.8 to 67.9
 Urban 152 41.9 40.6 32.1 to 49.2
Religious afflliation
 Christian 336 92.6 94.0 90.1 to 97.9
 Muslim 13 3.6 1.4 0.3 to 2.4
 No religion/other 14 3.9 4.7 0.8 to 8.5
Wealth index
 Poorest 51 14.0 14.7 9.5 to 19.9
 Second 92 25.3 25.8 18.5 to 33.2













Wafula et al. Page 10
Total Unweighted, N = 363
Variable Unweighted, n* Unweighted, % Weighted % 95% CI
 Third 84 23.1 24.3 18.6 to 30.0
 Fourth 84 23.1 21.4 15.4 to 27.5
 Richest 52 14.3 13.7 8.9 to 18.5
Time since diagnosis, months†
 ≤24 108 35.8 35.3 28.7 to 41.9
 25–48 66 21.9 20.5 15.5 to 25.6
 49–72 61 20.1 21.4 16.5 to 26.2
 >72 67 22.2 22.8 17.7 to 28.0
HIV care status
 Currently in care 326 89.8 89.9 86.0–93.7
 In care in past, but not currently in care 10 2.8 3.5 1.2 to 5.9
 Never in care 27 7.4 6.6 4.0 to 9.2
*
Because of missing responses totals vary between variables.
†
Data missing for 61 records.
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TABLE 2
Characteristics of HIV-Infected Adults and Adolescents Who Were Currently Receiving HIV Care, Kenya 
AIDS Indicator Survey 2012
Total, N = 326
Variable Unweighted, n* Weighted % 95% CI
Total
Sex
 Men 79 30.2 25.0 to 35.4
 Women 247 69.8 64.6 to 75.0
Age group, yrs
 15–29 62 18.4 13.8 to 23.1
 30–39 116 33.8 28.1 to 39.4
 40–49 89 29.8 23.9 to 35.7
 >50 59 18.0 13.4 to 22.6
Marital status
 Ever widowed 76 21.9 16.2 to 27.6
 Married/cohabiting 189 60.9 53.7 to 68.2
 Other 61 17.2 12.8 to 21.5
Highest educational attainment
 Primary or less 143 41.3 35.0 to 47.5
 Secondary/vocational 75 23.7 18.2 to 29.3
 College 108 35.0 28.2 to 41.8
Employed
 Yes 204 63.2 57.3 to 69.2
 No 122 36.8 30.8 to 42.7
Region
 Nairobi 35 8.7 6.5 to 10.9
 Central 30 8.7 5.6 to 11.8
 Coast 29 6.5 4.1 to 9.0
 Eastern 36 10.2 7.5 to 12.9
 Nyanza 134 41.2 33.5 to 48.9
 Rift Valley 28 13.7 8.4 to 19.0
 Western 34 11.0 5.6 to 16.4
Residence
 Rural 191 60.2 52.8 to 67.6
 Urban 135 39.8 32.4 to 47.2
Time since diagnosis, months
 ≤24 90 31.6 24.8 to 38.3
 25–48 62 21.3 15.8 to 26.7
 49–72 59 23.0 17.7 to 28.2
 >72 63 24.2 18.6 to 29.8
Wealth index
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Total, N = 326
Variable Unweighted, n* Weighted % 95% CI
 Poorest 45 14.6 9.2 to 20.0
 Second 84 26.8 19.0 to 34.7
 Third 77 24.8 18.6 to 30.9
 Fourth 73 20.2 14.3 to 26.1
 Richest 47 13.7 8.9 to 18.4
Time from diagnosis to entry into care, months
 3 or less 204 81.3 76.2 to 86.4
 More than 3 48 18.7 13.6 to 23.8
Time from last clinic visit, months
 3 or less 272 83.3 78.9 to 87.7
 More than 3 53 16.7 12.3 to 21.1
Current use of cotrimoxazole
 Yes 314 96.3 94.1 to 98.4
 No 11 3.7 1.6 to 5.9
Taking daily nutritional supplements
 Yes 93 29.0 22.5 to 35.4
 No 233 71.0 64.6 to 77.5
Ever had CD4+ T-cell count measured
 Yes 286 85.7 79.7 to 91.7
 No 40 14.3 8.3 to 20.3
*
Because of missing responses totals vary between variables.
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